http://www.medscape.com/viewarticle/772706
In an apparent effort to play King Solomon, the University of Texas System vice chancellor for health affairs has granted a limited waiver from the institution’s conflict-of-interest policy to the president of the University of Texas MD Anderson Cancer Center, The Houston Chronicle reports.
And the move is prompting criticism because because the cancer center president Ronald DePinho will be allowed to maintain financial ties with his three drugmakers. His holdings in Aveo Pharmaceuticals, Karyopharm and Metamark Genetics will be placed in a blind trust as part of the waiver, the paper writes.
This is clearly an interesting and unusual situation. The vice chancellor appears to be suggesting that real-world experience is useful to the school and apparently does not want to make a move that might prompte DePinho to exit. On the other hand, the critics make a point that a partial waiver suggests a slippery slope.
Source: Pharmalot
http://www.chron.com/news/houston-te...ep-3976008.php